Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

SVP, CHIEF ACCOUNTING OFFICER

PRESIDENT AND CEO

EVP, CHIEF BUSINESS OFFICER

SEE REMARKS

EVP, CHIEF FINANCIAL OFFICER

EVP, CHIEF OPERATING OFFICER

See Remarks

President and CEO

Chief Accounting Officer

EVP and General Counsel

EVP & CFO

Chief Operating Officer

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, a neoantigen-based immunotherapy, which is in Phase 2/3 clinical trials for the treatment of solid tumors, including microsatellite stable colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer a...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-02-01	Premium	acquired	Premium	Premium	Premium	SVP, CHIEF ACCOUNTING OFFICER
2024-02-01	Premium	acquired	Premium	Premium	Premium	PRESIDENT AND CEO
2024-02-01	Premium	acquired	Premium	Premium	Premium	EVP, CHIEF BUSINESS OFFICER
2024-02-01	Premium	acquired	Premium	Premium	Premium	SEE REMARKS
2024-02-01	Premium	acquired	Premium	Premium	Premium	EVP, CHIEF FINANCIAL OFFICER
2024-02-01	Premium	acquired	Premium	Premium	Premium	EVP, CHIEF OPERATING OFFICER
2023-05-23	Premium	bought	Premium	Premium	Premium	See Remarks
2023-02-02	Premium	acquired	Premium	Premium	Premium	See Remarks
2023-02-02	Premium	acquired	Premium	Premium	Premium	See Remarks
2023-02-02	Premium	acquired	Premium	Premium	Premium	President and CEO
2023-02-02	Premium	acquired	Premium	Premium	Premium	Chief Accounting Officer
2023-02-02	Premium	acquired	Premium	Premium	Premium	See Remarks
2023-02-02	Premium	acquired	Premium	Premium	Premium	See Remarks
2022-01-31	Premium	acquired	Premium	Premium	Premium	EVP and General Counsel
2022-01-31	Premium	acquired	Premium	Premium	Premium	President and CEO
2022-01-31	Premium	acquired	Premium	Premium	Premium	EVP & CFO
2022-01-31	Premium	acquired	Premium	Premium	Premium	See Remarks
2022-01-31	Premium	acquired	Premium	Premium	Premium	Chief Accounting Officer
2022-01-31	Premium	acquired	Premium	Premium	Premium	See Remarks
2022-01-31	Premium	acquired	Premium	Premium	Premium	Chief Operating Officer
2021-12-01	Premium	sold	Premium	Premium	Premium	Chief Operating Officer
2021-12-01	Premium	acquired	Premium	Premium	Premium	Chief Operating Officer
2021-11-01	Premium	acquired	Premium	Premium	Premium	Chief Operating Officer
2021-11-01	Premium	sold	Premium	Premium	Premium	See Remarks
2021-11-01	Premium	acquired	Premium	Premium	Premium	See Remarks

GRTS - Gritstone Oncology Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for GRTS